About Aceso
Aceso is committed to develop new therapy to better treat patients with respiratory diseases, such as cystic fibrosis
/ About
Read more
Advancing science with clarity, focus, and purpose.
A team built for scientific and operational excellence.
Read more
Building toward a new standard in drug discovery.
Who we are
ACESO Therapeutics is a biotech company focused on developing breakthrough therapeutic approaches for cystic fibrosis patients who remain underserved by current treatment options. Our work is grounded in scientific precision, translational research, and a belief that every patient deserves a path toward better breathing, stronger outcomes, and a better life quality.
Bench → bedside
Our journey
2013 — Patent 1
Scientific’s journey begins with Patent 1, focused on antisense oligonucleotide (ASO-TBS) with focus on Cystic Fribrosis
ASO-TBS (Target Site Blocker) technology initiated
Foundation of the scientific platform established
TECHNOLOGY FOCUS
2017 — R&D Collaboration
R&D academic collaboration between Biochemistry and Genetic laboratories, strengthening the early scientific foundation of the platform.
Genetics research expertise added
Biochemistry research expertise added
Support from Vaincre la Mucoviscidose, Fondation Maladies Rares and Fondation du Souffle
R&D COLLABORATION
2018 — Patent 2
Patent 2 filed
Peptide WRAP technology advanced for Cystic Fibrosis
PEPTIDE PLATFORM
2020 — SATT Grant
Technology grant by SATT to support proof-of-concept development and maturation toward TRL4.
2023 — ANR Grant
ANR grant to support continued scientific development and platform progression.
€500k funding awarded
2024 — Pipeline Progress
Aceso advances its scientific pipeline, building on earlier proof-of-concept work and strengthening translational development in respiratory diseases with focus on Cystic Fibrosis
Pipeline development accelerated
2025 — Focus on ACT-101
Aceso continues expanding its therapeutic platform with a focus on ACT-101 program novel RNA therapy for Cystic Fibrosis and next-stage development opportunities.
Focus on ACT-101
RESPIRATORY FOCUS
2026 — Clinical Readiness
Aceso prepares for clinical translation by progressing preclinical, regulatory, and development-readiness activities.
Preclinical-readiness activities progressed
Regulatory planning advanced
Clinical translation pathway strengthened
2027 — CTA Target
Aceso targets CTA progression for ACT-101 (TRL6), marking an important step toward clinical development.
ODD submission and CTA target for ACT-101
Clinical development pathway planned
Pipeline positioned for next-stage progression
Aceso’s scientific journey begins with Patent 1, focused on ASO-TBS.
FIRST PATENT
TECHNOLOGY FOCUS
Get in touch
Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.
